Preclinical Development of Novel Dual OXR/KOR Antagonists for Treatment of Substance Use Disorder — John A Butera (HAGER BIOSCIENC
ABSTRACT (Project Summary) Substance use disorder (SUD) characterized by the repeated use of an addictive substance leading to loss of intake control represents a serious public health and socio-econo
| Project title | Preclinical Development of Novel Dual OXR/KOR Antagonists for Treatment of Substance Use Disorder |
|---|---|
| Project number | 1UF1DA054817-01A1 |
| PI name | John A Butera |
| Institution | HAGER BIOSCIENCES, LLC |
| Funding mechanism | UF1 |
| Agency | NIDA |
| Award amount | $5.60M |
| Fiscal year | 2021 |
| Project start | 2021-09-30T00:00:00 |
| Project end | 2026-06-30T00:00:00 |
| Abstract | ABSTRACT (Project Summary) Substance use disorder (SUD) characterized by the repeated use of an addictive substance leading to loss of intake control represents a serious public health and socio-econo |
| Key terms | <ABC20><ABCB1><ABCB1 gene><Actiq><Acute><Address><Affect><Affective Disorders><Affinity><Animal Mode |
$799/mo
Try GrantRadar →